Literature DB >> 1422499

Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression.

R H Collins1, Z R Rogers, M Bennett, V Kumar, A Nikein, J W Fay.   

Abstract

Two patients with hematologic relapse of chronic myelogenous leukemia (CML) following allogeneic BMT were treated by abrupt discontinuation of cyclosporine. Both patients rapidly attained complete hematologic and cytogenetic remission and remain free of disease with long follow-up. In the first patient, disappearance of CML was associated with the development of graft-versus-host disease (GVHD). In the second patient GVHD did not develop until after clearing of disease had been documented by cytogenetic analysis. Laboratory studies in the second patient disclosed the presence of lytic activity against both K562 and autologous CML cells that enhanced with IL2. Correlation with serial immunophenotyping data from this patient suggests that the effector for this graft-versus-leukemia (GVL) reaction could have been a T lymphocyte. Abrupt discontinuation of post-transplant immunosuppression with cyclosporine may represent a therapeutic approach to CML which has recurred following BMT. Moreover, investigation of this clinical phenomenon in subsequent cases may permit direct study of the cellular mechanisms involved in the GVL effect.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1422499

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  15 in total

Review 1.  Filgrastim treatment of acute myelogenous leukemia (M7) relapse after allogeneic peripheral stem cell transplantation resulting in both graft-versus-leukemia effect with cytogenetic remission and chronic graft-versus-host disease manifesting as polyserositis and subsequent bronchiolitis obliterans with organizing pneumonia.

Authors:  L Law; J Tuscano; T Wun; K Ahlberg; C Richman
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

2.  Repeated donor lymphocyte infusions overcome a myeloid sarcoma of the stomach resulting from a relapse of acute myeloid leukemia after allogeneic cell transplantation in long-term survival of more than 10 years.

Authors:  Akinori Wada; Naoki Kobayashi; Shinsuke Asanuma; Satomi Matsuoka; Mizuha Kosugi; Shiro Fujii; Shinsuke Noguchi; Takayoshi Miyazono; Masanobu Nakata; Shuichi Ota; Kiyotoshi Imai; Teiichi Hirano; Masahiro Ogasawara; Yoshio Kiyama; Masaharu Kasai
Journal:  Int J Hematol       Date:  2010-12-23       Impact factor: 2.490

Review 3.  Novel approaches in allogeneic stem cell transplantation.

Authors:  Esperanza B Papadopoulos; Ann A Jakubowski
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

4.  Effective use of imatinib-mesylate in the treatment of relapsed chronic myeloid leukemia after allogeneic transplantation.

Authors:  Amjad Hayat; Shaun R McCann; Stephen Langabeer; Sandra Irvine; Mary Frances McMullin; Eibhlin Conneally
Journal:  Haematologica       Date:  2008-12-23       Impact factor: 9.941

Review 5.  Autografting as first line treatment for chronic myeloid leukaemia.

Authors:  I O Singer; I M Franklin
Journal:  J Clin Pathol       Date:  1998-02       Impact factor: 3.411

Review 6.  Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited.

Authors:  Abhinav Deol; Lawrence G Lum
Journal:  Cancer Treat Rev       Date:  2010-04-09       Impact factor: 12.111

7.  A long road of T-cells to cure cancer: from adoptive immunotherapy with unspecific cellular products to donor lymphocyte infusions and transfer of engineered tumor-specific T-cells.

Authors:  Alexandros Spyridonidis; Maria Liga
Journal:  Am J Blood Res       Date:  2012-05-18

8.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  David L Porter; Edwin P Alyea; Joseph H Antin; Marcos DeLima; Eli Estey; J H Frederik Falkenburg; Nancy Hardy; Nicolaus Kroeger; Jose Leis; John Levine; David G Maloney; Karl Peggs; Jacob M Rowe; Alan S Wayne; Sergio Giralt; Michael R Bishop; Koen van Besien
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-10       Impact factor: 5.742

9.  Cellular therapy following allogeneic stem-cell transplantation.

Authors:  Alison Rager; David L Porter
Journal:  Ther Adv Hematol       Date:  2011-12

Review 10.  Graft-versus-leukemia and graft-versus-lymphoma effects of allogeneic bone marrow transplantation and of allogeneic donor leukocyte transfusions.

Authors:  P Vandenberghe; M A Boogaerts
Journal:  Ann Hematol       Date:  1995-11       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.